公开(公告)号：WO2011130152A3

公开(公告)日：2012-02-23

申请号：PCT/US2011031906

申请日：2011-04-11

Applicant: ACADEMIA SINICA ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  WEI CHUN-YU

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  WEI CHUN-YU

IPC: G01N33/53 ,  C40B30/04 ,  C40B40/10 ,  G01N33/15 ,  G01N33/60

CPC classification number: G01N33/56977

Abstract: A method for identifying from an HLA library an HLA complex that specifically binds to a compound. This method can be relied on to assess whether a compound is likely to induce an adverse drug reaction and, if so, in which human population.

Abstract translation: 从HLA文库鉴定特异性结合化合物的HLA复合物的方法。 可以依靠这种方法来评估化合物是否有可能引起不良药物反应，如果是这样，则可以在哪一种人群中。

公开(公告)号：NZ597628A

公开(公告)日：2013-07-26

申请号：NZ59762807

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

Abstract: 597628 Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising: Detecting the presence of HLA-B*5801 in a sample obtained from the patient; and Correlating the presence of HLA-B*5801 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxypurinol.

公开(公告)号：NZ572259A

公开(公告)日：2012-03-30

申请号：NZ57225907

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

Abstract: Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising detecting the presence of HLA-B*1502 in a sample obtained from the patient, and correlating the presence of HLA-B*1502 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxcarbazepine.

公开(公告)号：PL2016198T3

公开(公告)日：2013-12-31

申请号：PL07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：AU2013219191A1

公开(公告)日：2013-09-12

申请号：AU2013219191

申请日：2013-08-21

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHANG CHI-FENG ,  SHEN CHIH-LUNG ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  CHEN WEI-HSUAN ,  LIN HSIN-YU

IPC: C12Q1/68

Abstract: The present invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for 5 developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：CA2651954A1

公开(公告)日：2007-11-22

申请号：CA2651954

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN WEI-HSUAN ,  LIN HSIN-YU ,  CHANG CHI-FENG ,  SHEN CHIH-LUNG ,  HUNG SHUEN-LU ,  CHEN YUAN-TSONG

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/02

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out t his method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the pres ence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B* 4601).

公开(公告)号：CA2651954C

公开(公告)日：2014-02-25

申请号：CA2651954

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/543

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：PT2016198E

公开(公告)日：2013-07-29

申请号：PT07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：DK2016198T3

公开(公告)日：2013-07-15

申请号：DK07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：AU2007249225B2

公开(公告)日：2013-06-27

申请号：AU2007249225

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHANG CHI-FENG ,  HUNG SHUEN-LU ,  CHEN WEI-HSUAN ,  CHEN YUAN-TSONG ,  SHEN CHIH-LUNG ,  LIN HSIN-YU

IPC: C12Q1/68

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).